Spero Therapeutics, Inc. posts annual revenue of $53.51 million in 2022

Spero Therapeutics, Inc. [SPRO] has reported $46.42 million loss for the fiscal year ending Dec 31, 2022.

Revenue for the year was $53.51 million with operating income of $42.20 million.

The Cambridge, Massachusetts (MA)-based company operating in the pharmaceutical preparations sector with 35 employees has total shareholders equity of $75.93 million.

Also read:

This is a developing story. Click here to receive updates.

------------

NewsInMinutes, an offering of 10kInfo, Inc., brings you news on the latest regulatory filings. Subscribe to additional news alerts here.